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Introduction
Pathologies of allergic and immune genesis are nowa-
days widespread due to advanced technologies, also of using 
synthetic substances in the pharmaceutical, food and agri-
cultural industries, and immunomodulatory drugs become 
a goal for many researchers [1, 2]. The fact that insects can 
produce substances that modulate the basic mechanisms of 
human immunity has been the basis for the synthesis from 
insects of new preparations with different pharmacological 
properties such as entomological preparations [3, 4, 2, 5], 
which by their lipoprotein and polysaccharide composition 
can be considered as compounds with an important immu-
nostimulatory potential [6, 7].
Imupurin, an entomological preparation obtained from 
butterflies, species Lepidoptera, the Lemantria family [6, 3, 
4] , due to the immunogenic amino acids and oligopeptides 
from  its composition possesses marked immunomodula-
tory properties that are capable to stimulate immune system 
[7,8,9] . It is recommended for complex treatment of pathol-
ogies developed due to immune system disorders [8, 9, 10].
Pregnancy, physiological condition characterized by ad-
ditional efforts of woman’s immunity [11], which on the one 
hand must adapt to the new conditions of embryo and fetus 
presence, on the other hand, the immune system must pro-
vide effective protection against infections or reactivation of 
existing pathologies of the mother [12]. It is important to re-
DOI: 10.5281/zenodo.2590005
UDC: 615.375.035.2:618.2/.3
Inoffensivity of imupurin in pregnancy
Ina Pogonea, MD, PhD, Associate Professor; *Carolina Catcov, MD, Assistant Professor;
Victor Ghicavii, MD, PhD, Professor, Corresponding Academician
Department of Pharmacology and Clinical Pharmacology
 Nicolae Testemitsanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova
*Corresponding author: carolina.catcov@usmf.md
Manuscript received February 01, 2019; revised manuscript March 04, 2019 
Abstract
Background: Determination of imupurin  inoffensivity on embryogenesis, organogenesis and teratogenesis in rats.
Material and methods: The study of immupurin’s safety during pregnancy was performed on 60 rats, divided into 4 groups. Animals from the control 
group were given 2 ml of physiological solution (NaCl, 0.9% ), and those from the experimental groups – 2 ml of imupurin suspension, internally, 1000 
mg / kg in different periods of pregnancy, to investigate embryotoxic, teratogenic and fetotoxic effect. The fetuses were monitored during the postnatal 
period, from birth to the age of 2 months, with appreciation of the physical development, the behavior and coordination of newborn movements, the 
evolution of body mass in dynamics, the teeth eruption, the appearance of the hair cover, the opening of the eyes, the ability to feed individually after 
removal from the female.
Results: The studies have shown that the pre-implantation and post-implantation indices in the control group were 4.1 and 3.8 respectively, and in 
experimental groups were 4.4 and 3.3. The number of live fetuses in the investigated groups was 12.1±1.5, which did not differ from the control group, 
whose live fetuses were 12.3±1.9.  Postnatal period indices (teeth eruption, hair cover, and eye opening) were similar in all investigated groups and 
corresponded to the age of the rats.
Conclusions: Imupurin has been shown to have no embryotoxic, fetotoxic and negative effects on the postnatal period and may be recommended in 
pathologies accompanying pregnancy.
Key words: entomotherapy, imupurin, fetotoxicity, pregnancy embryotoxicity.
member that pregnancy pathologies and a range of illnesses 
occurring during pregnancy evolve with more peculiarities 
and require medical treatment that needs double attention 
because the drugs can act on both the mother and the fetus 
[13]. In these situations, preparations which do not possess 
embryotoxic, fetotoxic or teratogenic effects are preferred.
Based on the above, we intend to investigate the embryo-
toxic, fetotoxic and teratogenic properties of imupurin in 
view of its inoffensivity in pregnancy [14].
Material and methods
Investigations of embryotoxicity, fetotoxicity and terato-
genicity of imupurin were performed according to contem-
porary recommendations [15,16].
In the study were used 60 matured, reproductive age al-
bino rats with a mass of 170-230 g, divided into four groups.
The studied substance (imupurin) was given endogas-
tral, 1000 mg per kg. The frequency of administration was 
once daily at the same time, according to the following 
schedule: Group No 1 was intact and served as a control; 
they were given the saline sol. NaCl, 0.9% – 2 ml, internal 
use. The females from the group No 2 received imupurin 
from the 1st the day of pregnancy to the 6th, group No 3 – 
from the 6th day to the 16th, group No 4 – from the 16th day 
to the 20th day (tab. 1). Animals were monitored daily.




Amount of the administered 
substance (mg) in suspen-




2 ml of saline solution, NaCl, 
0.9% + + +
II
(12 rats) Imupurin 1000 mg per kg + - -
III
(12 rats) Imupurin 1000 mg per kg - + -
IV
(12 rats) Imupurin 1000 mg per kg - - +
Postnatal development of newborns was studied 24 
hours from birth to 2 months old, and were appreciated the 
physical development, newborns behavior and movements 
coordination, evolution of body mass in dynamics, teeth 
eruption, the appearance of the hair cover, the opening of 
the eyes, the ability to feed individually after removal from 
the female 25 days after birth.
Results
The supervision of animals during experiences has not 
found deviations of behavior during pregnancy in females 
included in the study, compared with the control group.  Af-
ter imupurin administration, the rats became more active for 
10 minutes, with subsequent behavioral restoration, feeding 
and use of water was common without differentiation from 
the control group. Examination of the skin, mucous mem-
branes and hair cover did not show pathological changes. 
Once every 7 days they were weighed. The body weight of 
females on the average increased to 30 g in all groups. On 
the 20th day the animals were euthanized by dislocation of 
the cervical vertebrae and were determinated the following 
indices: embryonic mortality in pre- and post-implantation 
periods, developmental malformations, general retention of 
the development of the fetuses. Pre-implantation mortal-
ity was determined by the difference between the number 
of yellow bodies in the ovaries and the number of places 
implanted in the uterus. Later we determined the post-im-
plantation index – by the difference between the number of 
implanted places and the number of live embryos.
The analysis of the investigated indices did not reveal sig-
nificant deviations in the females from imupurin lots com-
pared to the control regarding the number of yellow bodies, 
the number of implant sites, the number of live and dead 
females, the number of resorptions (tab. 2). No significant 
differences were found between experimental and control 
groups in mortality determination in the pre-implantation 
and post-implant period.
The number of newborns from the females who received 
imupurin corresponds to the number of fetuses born from 
the control group’s females. 
Table 2
Influence of imupurin on the embryotoxicity, 
teratogenicity and fetotoxicity parameters
Investigation indices Imupurin Control
Number of pregnant females 26 30
Number of yellow bodies 13.3 ± 1.6 13.9 ± 2.4
Number of implant sites 12.7 ± 1.3 13.3 ± 2.3
Number of live fetuses 12.8 ± 1.5 12.7 ± 1.9
Number of resorbtions 0.2 ± 0.4 0.3 ± 0.5
Number of dead fetuses 0.2 ± 0.4 0.3 ± 0.7
Mortality at preimplantation stage (%) 4.4 4.1
Mortality at postimplantation stage (%) 3.3 3.8
Fetuses weight 3.2 ± 0.29 3.3 ± 0.25
The weight of the fetuses in the investigated groups did 
not differ from the control and constituted an average of 
3.2±0.3. Also, there were no significant differences in the 
number of fetuses per female, which was 12.1±1.5 in the 
study groups which received imupurin, once daily, com-
pared to the control group. The mortality cases of the fetuses 
were few – 3.3% in the investigated group and 3.8% in the 
control group. Mortality during pre-implantation and post-
implantation is not statistically significant (tab. 2).
In all study groups were not detected disturbances in the 
development of embryo-amniotic fluid which was trans-
parent; fetal membranes were normally developed, well 
vascularized, without sclerosis. At the opening of the fetal 
membranes and the umbilical cord section, appeared the 
spontaneous breath of the fetuses. The skin was rosy, eyes 
and ears – covered. No external abnormalities of the skel-
eton and internal organs have been detected in the morpho-
logical research of the fetuses.
The postnatal behavior of rats undergoing study did not 
differ from those in the control group. After euthanasia of 
newborns, development abnormalities were not detected.
All rats were removed from natural food on the 26th day 
of life. Adaptation to artificial foods was in the early hours. 
Analysis of postnatal indices did not reveal significant de-
viations regarding the detachment of the ear pavilion, the 
teeth eruption, the appearance of the hair cover, the opening 
of the eyes (tab. 3).
Table 3
Appearance indices
The studied indices Time of appearance
Detachment of the ear pavilion Day 4
Tooth eruption Day 8
The appearance of the hair cover Day 11
Opening of eyes Day 15
Conclusions
1.  Entomological preparation did not influence the be-
havior of pregnant females throughout the pregnancy.
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2.  Imupurin did not show embryotoxic, teratogenic and 
fetotoxic properties.
3.  The postnatal development of fetuses born to females 
which have been given imupurin was similar to the animals 
in the control group.
References
1. Catcov C, Pogonea I, Ghicavii V. Artropodele – o sursă bogată de medi-
camente [Arthropodes – a rich source of medicines]. Sănătate Publică, 
Economie şi Management în Medicină (Chisinau). 2018;(4(78)):93-96. 
Romanian.
2. Ciuhrii M. Fauna în tratarea şi alimentarea omului [Fauna in human 
treatment and alimentation]. 2006. Romanian.
3. Bacinschi N, Ghicavii V, Pogonea I. Peptide din insecte – sursă de 
preparate cu acţiune antimicrobiană [Peptides from insects – source of 
preparations with an antimicrobial action]. Revista de Ştiinţă, Inovare, 
Cultură şi Artă „Akademos” (Chisinau). 2013;(4(31)):94-99. ISSN 
1857-0461. Romanian.
4. Bacinschi N, Ghicavii V, Pogonea I. Peptide din insecte cu acţiune 
antivirală şi antitumorală [Peptides from insects with antiviral and 
antitumoral action]. Anale Ştiinţifice ale USMF „Nicolae Testemiţanu” 
(Chisinau). 2012;1:196-201. ISSN 1857-1719. Romanian.
5. Costa-Neto EM. Entomotherapy, or the medicinal use of insects. J 
Ethnobiol. 2005;25(1):93-114.
6. Bacinschi N. Preparate entomologice cu proprietăţi imunotrope [En-
tomologic remedies with immunotrop properties]. Curierul Medical 
(Chisinau). 2010(6):3-8. Romanian.
7. Ghicavii V, Pogonea I, Bacinschi N, Ghinda S. Acţiunea entomoprepa-
ratelor asupra imunităţii umorale şi celulare [Action of entomological 
drugs on humoral and cellular immunity]. Anale Ştiinţifice ale USMF 
„Nicolae Testemiţanu” (Chisinau). 2013;1:236-239. ISSN 1857-1719. 
Romanian.
8. Ghicavii V, Pogonea I, Bacinschi N, et al. Optimizarea tratamentului 
complex al unor imunodeficienţe [Optimizing the complex treatment 
of some immonodeficiencies]. Chişinău: Medicina; 2011. 24 p.
9. Ivanov E, Pogonea I, et al. Evolutia maladiei HIV/ SIDA pe fondal de 
tratament cu un nou preparat entomologic – imupurin [Evolution 
of AIDS on the background of treatment with a new entomological 
preparation – imupurin].  Anale ştiinţifice ale USMF „Nicolae Teste-
mitanu” (Chisinau). 2010;1:343-346. Romanian.
10. Pogonea I, Ghicavii V, Ghinda S. Noi medicamente imunocorectoare 
de origine entomologică [New immunocorective entomological 
drugs]. Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale. 
2016;(1(50)):205-208. ISSN 1857-0011. Romanian.
11. Bonney EA. Immune regulation in pregnancy: a matter of perspective? 
Obstet Gynecol Clin North Am. 2016 Dec;43(4):679-698.
12. Rychlik KA, Sillé FCM. Environmental exposures during pregnancy: 
Mechanistic effects on immunity. Birth Defects Res. 2019 Feb 1. doi: 
10.1002/bdr2.1469.
13. Malm H, Ellfolk M. Which drugs can be used during pregnancy? 
Duodecim. 2016;132(19):1781-9.
14. Konstantinova N, Pogonea I. Study of embryotoxic, fetotoxic and 
teratogenic properties of entomologic drugs. In:  MedEspera 2012: 
4th International Medical Congress for Students and Young Doctors; 
2012 May 17-19; Chisinau; 2012. 274 p.
15. Vogel HG, ed. Drug discovery and evaluation: pharmacological assays. 
3rd ed. Berlin: Springer; 2008. 2071 p. ISBN: 978-3-540-70995-4.
16. Habriev RU, ed. Rukovodstvo po experimental’nomu  (doklinichesko-
mu ) izucheniiu novykh farmakologicheskikh veshchestv [Manual on 
experimental (preclinical) study of new pharmacological substances]. 
2nd ed. Мoscow: Meditsina; 2005. 832 p. Russian.
